Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?

Author(s): Valentina Echeverria, J. Alex Grizzell, George E. Barreto.

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 10 , 2016

Submit Manuscript
Submit Proposal

Abstract:

Neuroinflammation is a common characteristic of several mental health conditions such as major depression, bipolar disorder, post-traumatic stress disorder (PTSD) and schizophrenia (SCHZ). Inflammatory processes trigger and/or further deteriorate mental functions and are regarded as targets for therapeutic drug development. Cotinine is an alkaloid present in tobacco leaves and the main metabolite of nicotine. Cotinine is safe, non-addictive and has pharmacokinetic properties adequate for therapeutic use. Research has shown that cotinine has antipsychotic, anxiolytic, and antidepressant properties and modulates the serotonergic, cholinergic and dopaminergic systems. Consistent with the modulation of these neurotransmitter systems, cotinine behaves as a positive allosteric modulator of the nicotinic acetylcholine receptors (nAChRs) and has anti-inflammatory effects. The decrease in neuroinflammation induced by the stimulation of the cholinergic system seems to be a key element explaining the beneficial effects of cotinine in a diverse range of neurological and psychiatric conditions. This review discusses new evidence of the role of neuroinflammation as a key aspect in bipolar disorder, PTSD and major depression, as well as the potential use of cotinine to reduce neuroinflammation in those conditions.

Keywords: Neuroinflammation, Major depression, cotinine, Post-traumatic stress disorder, Bipolar disorder, suicide, anxiety.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 22
ISSUE: 10
Year: 2016
Page: [1324 - 1333]
Pages: 10
DOI: 10.2174/138161282210160304112511
Price: $58

Article Metrics

PDF: 56
HTML: 2
EPUB: 1
PRC: 4